Beta	B:C0001645
-Adrenergic	I:C0001645
Receptor	I:C0001645
Blockers	I:C0001645
in	O
Hypertension	O
:	O
Alive	O
and	O
Well	O
.	O

Beta	O
-Adrenergic	I:C0001645
Receptor	I:C0001645
Blockers	I:C0001645
in	O
Hypertension	B:C0020538
:	O
Alive	O
and	O
Well	O
.	O

Beta-	B:C0001645
adrenergic	I:C0001645
receptor	I:C0001645
blockers	I:C0001645
(	O
β	O
-	I:C0001645
blockers	I:C0001645
)	O
are	O
an	O
appropriate	O
treatment	O
for	O
patients	O
having	O
systemic	O
hypertension	I:C0020538
(	O
hypertension	O
)	O
who	O
have	O
concomitant	O
ischemic	I:C0151744
heart	I:C0151744
disease	I:C0151744
(	O
ischemic	O
heart	I:C0151744
disease	I:C0151744
)	O
,	O
heart	O
failure	I:C0018801
,	O
obstructive	O
cardiomyopathy	I:C0007194
,	O
aortic	O
dissection	I:C0340643
or	O
certain	O
cardiac	O
arrhythmias	I:C0003811
.	O

Beta-	O
adrenergic	I:C0001645
receptor	I:C0001645
blockers	I:C0001645
(	O
β	B:C0001645
-	I:C0001645
blockers	I:C0001645
)	O
are	O
an	O
appropriate	O
treatment	O
for	O
patients	O
having	O
systemic	O
hypertension	I:C0020538
(	O
hypertension	O
)	O
who	O
have	O
concomitant	O
ischemic	I:C0151744
heart	I:C0151744
disease	I:C0151744
(	O
ischemic	O
heart	I:C0151744
disease	I:C0151744
)	O
,	O
heart	O
failure	I:C0018801
,	O
obstructive	O
cardiomyopathy	I:C0007194
,	O
aortic	O
dissection	I:C0340643
or	O
certain	O
cardiac	O
arrhythmias	I:C0003811
.	O

Beta-	O
adrenergic	I:C0001645
receptor	I:C0001645
blockers	I:C0001645
(	O
β	O
-	I:C0001645
blockers	I:C0001645
)	O
are	O
an	O
appropriate	O
treatment	B:C0087111
for	O
patients	O
having	O
systemic	O
hypertension	I:C0020538
(	O
hypertension	O
)	O
who	O
have	O
concomitant	O
ischemic	I:C0151744
heart	I:C0151744
disease	I:C0151744
(	O
ischemic	O
heart	I:C0151744
disease	I:C0151744
)	O
,	O
heart	O
failure	I:C0018801
,	O
obstructive	O
cardiomyopathy	I:C0007194
,	O
aortic	O
dissection	I:C0340643
or	O
certain	O
cardiac	O
arrhythmias	I:C0003811
.	O

Beta-	O
adrenergic	I:C0001645
receptor	I:C0001645
blockers	I:C0001645
(	O
β	O
-	I:C0001645
blockers	I:C0001645
)	O
are	O
an	O
appropriate	O
treatment	O
for	O
patients	O
having	O
systemic	B:C0020538
hypertension	I:C0020538
(	O
hypertension	O
)	O
who	O
have	O
concomitant	O
ischemic	I:C0151744
heart	I:C0151744
disease	I:C0151744
(	O
ischemic	O
heart	I:C0151744
disease	I:C0151744
)	O
,	O
heart	O
failure	I:C0018801
,	O
obstructive	O
cardiomyopathy	I:C0007194
,	O
aortic	O
dissection	I:C0340643
or	O
certain	O
cardiac	O
arrhythmias	I:C0003811
.	O

Beta-	O
adrenergic	I:C0001645
receptor	I:C0001645
blockers	I:C0001645
(	O
β	O
-	I:C0001645
blockers	I:C0001645
)	O
are	O
an	O
appropriate	O
treatment	O
for	O
patients	O
having	O
systemic	O
hypertension	I:C0020538
(	O
hypertension	B:C0020538
)	O
who	O
have	O
concomitant	O
ischemic	I:C0151744
heart	I:C0151744
disease	I:C0151744
(	O
ischemic	O
heart	I:C0151744
disease	I:C0151744
)	O
,	O
heart	O
failure	I:C0018801
,	O
obstructive	O
cardiomyopathy	I:C0007194
,	O
aortic	O
dissection	I:C0340643
or	O
certain	O
cardiac	O
arrhythmias	I:C0003811
.	O

Beta-	O
adrenergic	I:C0001645
receptor	I:C0001645
blockers	I:C0001645
(	O
β	O
-	I:C0001645
blockers	I:C0001645
)	O
are	O
an	O
appropriate	O
treatment	O
for	O
patients	O
having	O
systemic	O
hypertension	I:C0020538
(	O
hypertension	O
)	O
who	O
have	O
concomitant	B:C0151744
ischemic	I:C0151744
heart	I:C0151744
disease	I:C0151744
(	O
ischemic	O
heart	I:C0151744
disease	I:C0151744
)	O
,	O
heart	O
failure	I:C0018801
,	O
obstructive	O
cardiomyopathy	I:C0007194
,	O
aortic	O
dissection	I:C0340643
or	O
certain	O
cardiac	O
arrhythmias	I:C0003811
.	O

Beta-	O
adrenergic	I:C0001645
receptor	I:C0001645
blockers	I:C0001645
(	O
β	O
-	I:C0001645
blockers	I:C0001645
)	O
are	O
an	O
appropriate	O
treatment	O
for	O
patients	O
having	O
systemic	O
hypertension	I:C0020538
(	O
hypertension	O
)	O
who	O
have	O
concomitant	O
ischemic	I:C0151744
heart	I:C0151744
disease	I:C0151744
(	O
ischemic	B:C0151744
heart	I:C0151744
disease	I:C0151744
)	O
,	O
heart	O
failure	I:C0018801
,	O
obstructive	O
cardiomyopathy	I:C0007194
,	O
aortic	O
dissection	I:C0340643
or	O
certain	O
cardiac	O
arrhythmias	I:C0003811
.	O

Beta-	O
adrenergic	I:C0001645
receptor	I:C0001645
blockers	I:C0001645
(	O
β	O
-	I:C0001645
blockers	I:C0001645
)	O
are	O
an	O
appropriate	O
treatment	O
for	O
patients	O
having	O
systemic	O
hypertension	I:C0020538
(	O
hypertension	O
)	O
who	O
have	O
concomitant	O
ischemic	I:C0151744
heart	I:C0151744
disease	I:C0151744
(	O
ischemic	O
heart	I:C0151744
disease	I:C0151744
)	O
,	O
heart	B:C0018801
failure	I:C0018801
,	O
obstructive	O
cardiomyopathy	I:C0007194
,	O
aortic	O
dissection	I:C0340643
or	O
certain	O
cardiac	O
arrhythmias	I:C0003811
.	O

Beta-	O
adrenergic	I:C0001645
receptor	I:C0001645
blockers	I:C0001645
(	O
β	O
-	I:C0001645
blockers	I:C0001645
)	O
are	O
an	O
appropriate	O
treatment	O
for	O
patients	O
having	O
systemic	O
hypertension	I:C0020538
(	O
hypertension	O
)	O
who	O
have	O
concomitant	O
ischemic	I:C0151744
heart	I:C0151744
disease	I:C0151744
(	O
ischemic	O
heart	I:C0151744
disease	I:C0151744
)	O
,	O
heart	O
failure	I:C0018801
,	O
obstructive	B:C0007194
cardiomyopathy	I:C0007194
,	O
aortic	O
dissection	I:C0340643
or	O
certain	O
cardiac	O
arrhythmias	I:C0003811
.	O

Beta-	O
adrenergic	I:C0001645
receptor	I:C0001645
blockers	I:C0001645
(	O
β	O
-	I:C0001645
blockers	I:C0001645
)	O
are	O
an	O
appropriate	O
treatment	O
for	O
patients	O
having	O
systemic	O
hypertension	I:C0020538
(	O
hypertension	O
)	O
who	O
have	O
concomitant	O
ischemic	I:C0151744
heart	I:C0151744
disease	I:C0151744
(	O
ischemic	O
heart	I:C0151744
disease	I:C0151744
)	O
,	O
heart	O
failure	I:C0018801
,	O
obstructive	O
cardiomyopathy	I:C0007194
,	O
aortic	B:C0340643
dissection	I:C0340643
or	O
certain	O
cardiac	O
arrhythmias	I:C0003811
.	O

Beta-	O
adrenergic	I:C0001645
receptor	I:C0001645
blockers	I:C0001645
(	O
β	O
-	I:C0001645
blockers	I:C0001645
)	O
are	O
an	O
appropriate	O
treatment	O
for	O
patients	O
having	O
systemic	O
hypertension	I:C0020538
(	O
hypertension	O
)	O
who	O
have	O
concomitant	O
ischemic	I:C0151744
heart	I:C0151744
disease	I:C0151744
(	O
ischemic	O
heart	I:C0151744
disease	I:C0151744
)	O
,	O
heart	O
failure	I:C0018801
,	O
obstructive	O
cardiomyopathy	I:C0007194
,	O
aortic	O
dissection	I:C0340643
or	O
certain	O
cardiac	B:C0003811
arrhythmias	I:C0003811
.	O

β-	B:C0001645
Blockers	I:C0001645
can	O
be	O
used	O
in	O
combination	O
with	O
other	O
antiHTN	O
drugs	I:C0003364
to	O
achieve	O
maximal	O
blood	I:C1753303
pressure	I:C1753303
control	I:C1753303
.	O

β-	O
Blockers	I:C0001645
can	O
be	O
used	O
in	O
combination	O
with	O
other	O
antiHTN	B:C0003364
drugs	I:C0003364
to	O
achieve	O
maximal	O
blood	I:C1753303
pressure	I:C1753303
control	I:C1753303
.	O

β-	O
Blockers	I:C0001645
can	O
be	O
used	O
in	O
combination	O
with	O
other	O
antiHTN	O
drugs	I:C0003364
to	O
achieve	O
maximal	B:C1753303
blood	I:C1753303
pressure	I:C1753303
control	I:C1753303
.	O

Labetalol	B:C0022860
can	O
be	O
used	O
in	O
HTN	O
emergencies	I:C0745136
and	O
urgencies	O
.	O

Labetalol	O
can	O
be	O
used	O
in	O
HTN	B:C0745136
emergencies	I:C0745136
and	O
urgencies	O
.	O

Labetalol	O
can	O
be	O
used	O
in	O
HTN	O
emergencies	I:C0745136
and	O
urgencies	B:C0745138
.	O

β-	B:C0001645
Blockers	I:C0001645
may	O
be	O
useful	O
in	O
hypertension	O
patients	O
having	O
a	O
hyperkinetic	O
circulation	O
(	O
palpitations	O
,	O
tachycardia	O
,	O
hypertension	O
,	O
and	O
anxiety	O
)	O
,	O
migraine	O
headache	I:C0149931
,	O
and	O
essential	O
tremor	I:C0270736
.	O

β-	O
Blockers	I:C0001645
may	O
be	O
useful	O
in	O
hypertension	B:C0020538
patients	O
having	O
a	O
hyperkinetic	O
circulation	O
(	O
palpitations	O
,	O
tachycardia	O
,	O
hypertension	O
,	O
and	O
anxiety	O
)	O
,	O
migraine	O
headache	I:C0149931
,	O
and	O
essential	O
tremor	I:C0270736
.	O

β-	O
Blockers	I:C0001645
may	O
be	O
useful	O
in	O
hypertension	O
patients	O
having	O
a	O
hyperkinetic	O
circulation	B:C0005775
(	O
palpitations	O
,	O
tachycardia	O
,	O
hypertension	O
,	O
and	O
anxiety	O
)	O
,	O
migraine	O
headache	I:C0149931
,	O
and	O
essential	O
tremor	I:C0270736
.	O

β-	O
Blockers	I:C0001645
may	O
be	O
useful	O
in	O
hypertension	O
patients	O
having	O
a	O
hyperkinetic	O
circulation	O
(	O
palpitations	B:C0030252
,	O
tachycardia	O
,	O
hypertension	O
,	O
and	O
anxiety	O
)	O
,	O
migraine	O
headache	I:C0149931
,	O
and	O
essential	O
tremor	I:C0270736
.	O

β-	O
Blockers	I:C0001645
may	O
be	O
useful	O
in	O
hypertension	O
patients	O
having	O
a	O
hyperkinetic	O
circulation	O
(	O
palpitations	O
,	O
tachycardia	B:C0039231
,	O
hypertension	O
,	O
and	O
anxiety	O
)	O
,	O
migraine	O
headache	I:C0149931
,	O
and	O
essential	O
tremor	I:C0270736
.	O

β-	O
Blockers	I:C0001645
may	O
be	O
useful	O
in	O
hypertension	O
patients	O
having	O
a	O
hyperkinetic	O
circulation	O
(	O
palpitations	O
,	O
tachycardia	O
,	O
hypertension	B:C0020538
,	O
and	O
anxiety	O
)	O
,	O
migraine	O
headache	I:C0149931
,	O
and	O
essential	O
tremor	I:C0270736
.	O

β-	O
Blockers	I:C0001645
may	O
be	O
useful	O
in	O
hypertension	O
patients	O
having	O
a	O
hyperkinetic	O
circulation	O
(	O
palpitations	O
,	O
tachycardia	O
,	O
hypertension	O
,	O
and	O
anxiety	B:C0003467
)	O
,	O
migraine	O
headache	I:C0149931
,	O
and	O
essential	O
tremor	I:C0270736
.	O

β-	O
Blockers	I:C0001645
may	O
be	O
useful	O
in	O
hypertension	O
patients	O
having	O
a	O
hyperkinetic	O
circulation	O
(	O
palpitations	O
,	O
tachycardia	O
,	O
hypertension	O
,	O
and	O
anxiety	O
)	O
,	O
migraine	B:C0149931
headache	I:C0149931
,	O
and	O
essential	O
tremor	I:C0270736
.	O

β-	O
Blockers	I:C0001645
may	O
be	O
useful	O
in	O
hypertension	O
patients	O
having	O
a	O
hyperkinetic	O
circulation	O
(	O
palpitations	O
,	O
tachycardia	O
,	O
hypertension	O
,	O
and	O
anxiety	O
)	O
,	O
migraine	O
headache	I:C0149931
,	O
and	O
essential	B:C0270736
tremor	I:C0270736
.	O

β-	B:C0001645
Blockers	I:C0001645
are	O
highly	O
heterogeneous	O
with	O
respect	O
to	O
various	O
pharmacologic	O
properties	O
:	O
degree	O
of	I:C0877014
intrinsic	I:C0877014
sympathomimetic	I:C0877014
activity	I:C0877014
,	O
membrane	O
stabilizing	O
activity	O
,	O
β	O
1	I:C1152727
selectivity	I:C1152727
,	O
α1	O
-	I:C1152724
adrenergic	I:C1152724
blocking	I:C1152724
effects	I:C1152724
,	O
tissue	O
solubility	O
,	O
routes	O
of	I:C0231360
systemic	I:C0231360
elimination	I:C0231360
,	O
potencies	O
and	O
duration	O
of	O
action	O
,	O
and	O
specific	O
properties	O
may	O
be	O
important	O
in	O
the	O
selection	O
of	I:C0013175
a	I:C0013175
drug	I:C0013175
for	I:C0013175
clinical	I:C0013175
use	I:C0013175
.	O

β-	O
Blockers	I:C0001645
are	O
highly	O
heterogeneous	O
with	O
respect	O
to	O
various	O
pharmacologic	O
properties	O
:	O
degree	B:C0877014
of	I:C0877014
intrinsic	I:C0877014
sympathomimetic	I:C0877014
activity	I:C0877014
,	O
membrane	O
stabilizing	O
activity	O
,	O
β	O
1	I:C1152727
selectivity	I:C1152727
,	O
α1	O
-	I:C1152724
adrenergic	I:C1152724
blocking	I:C1152724
effects	I:C1152724
,	O
tissue	O
solubility	O
,	O
routes	O
of	I:C0231360
systemic	I:C0231360
elimination	I:C0231360
,	O
potencies	O
and	O
duration	O
of	O
action	O
,	O
and	O
specific	O
properties	O
may	O
be	O
important	O
in	O
the	O
selection	O
of	I:C0013175
a	I:C0013175
drug	I:C0013175
for	I:C0013175
clinical	I:C0013175
use	I:C0013175
.	O

β-	O
Blockers	I:C0001645
are	O
highly	O
heterogeneous	O
with	O
respect	O
to	O
various	O
pharmacologic	O
properties	O
:	O
degree	O
of	I:C0877014
intrinsic	I:C0877014
sympathomimetic	I:C0877014
activity	I:C0877014
,	O
membrane	O
stabilizing	O
activity	O
,	O
β	B:C1152727
1	I:C1152727
selectivity	I:C1152727
,	O
α1	O
-	I:C1152724
adrenergic	I:C1152724
blocking	I:C1152724
effects	I:C1152724
,	O
tissue	O
solubility	O
,	O
routes	O
of	I:C0231360
systemic	I:C0231360
elimination	I:C0231360
,	O
potencies	O
and	O
duration	O
of	O
action	O
,	O
and	O
specific	O
properties	O
may	O
be	O
important	O
in	O
the	O
selection	O
of	I:C0013175
a	I:C0013175
drug	I:C0013175
for	I:C0013175
clinical	I:C0013175
use	I:C0013175
.	O

β-	O
Blockers	I:C0001645
are	O
highly	O
heterogeneous	O
with	O
respect	O
to	O
various	O
pharmacologic	O
properties	O
:	O
degree	O
of	I:C0877014
intrinsic	I:C0877014
sympathomimetic	I:C0877014
activity	I:C0877014
,	O
membrane	O
stabilizing	O
activity	O
,	O
β	O
1	I:C1152727
selectivity	I:C1152727
,	O
α1	B:C1152724
-	I:C1152724
adrenergic	I:C1152724
blocking	I:C1152724
effects	I:C1152724
,	O
tissue	O
solubility	O
,	O
routes	O
of	I:C0231360
systemic	I:C0231360
elimination	I:C0231360
,	O
potencies	O
and	O
duration	O
of	O
action	O
,	O
and	O
specific	O
properties	O
may	O
be	O
important	O
in	O
the	O
selection	O
of	I:C0013175
a	I:C0013175
drug	I:C0013175
for	I:C0013175
clinical	I:C0013175
use	I:C0013175
.	O

β-	O
Blockers	I:C0001645
are	O
highly	O
heterogeneous	O
with	O
respect	O
to	O
various	O
pharmacologic	O
properties	O
:	O
degree	O
of	I:C0877014
intrinsic	I:C0877014
sympathomimetic	I:C0877014
activity	I:C0877014
,	O
membrane	O
stabilizing	O
activity	O
,	O
β	O
1	I:C1152727
selectivity	I:C1152727
,	O
α1	O
-	I:C1152724
adrenergic	I:C1152724
blocking	I:C1152724
effects	I:C1152724
,	O
tissue	O
solubility	O
,	O
routes	B:C0231360
of	I:C0231360
systemic	I:C0231360
elimination	I:C0231360
,	O
potencies	O
and	O
duration	O
of	O
action	O
,	O
and	O
specific	O
properties	O
may	O
be	O
important	O
in	O
the	O
selection	O
of	I:C0013175
a	I:C0013175
drug	I:C0013175
for	I:C0013175
clinical	I:C0013175
use	I:C0013175
.	O

β-	O
Blockers	I:C0001645
are	O
highly	O
heterogeneous	O
with	O
respect	O
to	O
various	O
pharmacologic	O
properties	O
:	O
degree	O
of	I:C0877014
intrinsic	I:C0877014
sympathomimetic	I:C0877014
activity	I:C0877014
,	O
membrane	O
stabilizing	O
activity	O
,	O
β	O
1	I:C1152727
selectivity	I:C1152727
,	O
α1	O
-	I:C1152724
adrenergic	I:C1152724
blocking	I:C1152724
effects	I:C1152724
,	O
tissue	O
solubility	O
,	O
routes	O
of	I:C0231360
systemic	I:C0231360
elimination	I:C0231360
,	O
potencies	O
and	O
duration	O
of	O
action	O
,	O
and	O
specific	O
properties	O
may	O
be	O
important	O
in	O
the	O
selection	B:C0013175
of	I:C0013175
a	I:C0013175
drug	I:C0013175
for	I:C0013175
clinical	I:C0013175
use	I:C0013175
.	O

β-	O
Blocker	O
usage	O
to	O
reduce	O
perioperative	O
myocardial	B:C0151744
ischemia	I:C0151744
and	O
cardiovascular	O
(	I:C0161816
CV	I:C0161816
)	I:C0161816
complications	I:C0161816
may	O
not	O
benefit	O
as	O
many	O
patients	O
as	O
was	O
once	O
hoped	O
,	O
and	O
may	O
actually	O
cause	O
harm	O
in	O
some	O
individuals	O
.	O

β-	O
Blocker	O
usage	O
to	O
reduce	O
perioperative	O
myocardial	O
ischemia	I:C0151744
and	O
cardiovascular	B:C0161816
(	I:C0161816
CV	I:C0161816
)	I:C0161816
complications	I:C0161816
may	O
not	O
benefit	O
as	O
many	O
patients	O
as	O
was	O
once	O
hoped	O
,	O
and	O
may	O
actually	O
cause	O
harm	O
in	O
some	O
individuals	O
.	O

Currently	O
the	O
best	O
evidence	O
supports	O
perioperative	O
β-	O
blocker	O
use	O
in	O
two	O
patient	O
groups	O
:	O
patients	O
undergoing	O
vascular	B:C0042381
surgery	I:C0042381
with	O
known	O
ischemic	O
heart	I:C0151744
disease	I:C0151744
or	O
multiple	O
risk	O
factors	O
for	O
it	O
,	O
and	O
for	O
those	O
patients	O
already	O
receiving	O
β-	O
blockers	I:C0001645
for	O
known	O
CV	O
conditions	I:C0161816
.	O

Currently	O
the	O
best	O
evidence	O
supports	O
perioperative	O
β-	O
blocker	O
use	O
in	O
two	O
patient	O
groups	O
:	O
patients	O
undergoing	O
vascular	O
surgery	I:C0042381
with	O
known	O
ischemic	B:C0151744
heart	I:C0151744
disease	I:C0151744
or	O
multiple	O
risk	O
factors	O
for	O
it	O
,	O
and	O
for	O
those	O
patients	O
already	O
receiving	O
β-	O
blockers	I:C0001645
for	O
known	O
CV	O
conditions	I:C0161816
.	O

Currently	O
the	O
best	O
evidence	O
supports	O
perioperative	O
β-	O
blocker	O
use	O
in	O
two	O
patient	O
groups	O
:	O
patients	O
undergoing	O
vascular	O
surgery	I:C0042381
with	O
known	O
ischemic	O
heart	I:C0151744
disease	I:C0151744
or	O
multiple	O
risk	O
factors	O
for	O
it	O
,	O
and	O
for	O
those	O
patients	O
already	O
receiving	O
β-	B:C0001645
blockers	I:C0001645
for	O
known	O
CV	O
conditions	I:C0161816
.	O

Currently	O
the	O
best	O
evidence	O
supports	O
perioperative	O
β-	O
blocker	O
use	O
in	O
two	O
patient	O
groups	O
:	O
patients	O
undergoing	O
vascular	O
surgery	I:C0042381
with	O
known	O
ischemic	O
heart	I:C0151744
disease	I:C0151744
or	O
multiple	O
risk	O
factors	O
for	O
it	O
,	O
and	O
for	O
those	O
patients	O
already	O
receiving	O
β-	O
blockers	I:C0001645
for	O
known	O
CV	B:C0161816
conditions	I:C0161816
.	O

